Literature DB >> 14675598

Incidence of aspirin nonresponsiveness using the Ultegra Rapid Platelet Function Assay-ASA.

John C Wang1, Denise Aucoin-Barry, Deborah Manuelian, Rachele Monbouquette, Mark Reisman, William Gray, Peter C Block, Elizabeth H Block, Marc Ladenheim, Daniel I Simon.   

Abstract

We report the incidence of aspirin nonresponsiveness in a prospective, multicenter registry (n=422 patients) to be 23% using the Ultegra Rapid Platelet Function Assay-ASA, and determined a history of coronary artery disease to be associated with twice the odds of being an aspirin nonresponder (odds ratio 2.01, 95% confidence interval 1.189 to 3.411, p=0.009). Further prospective studies are needed to correlate aspirin nonresponsiveness to adverse clinical events.

Entities:  

Mesh：

Substances：

Year:  2003        PMID： 14675598     DOI： 10.1016/j.amjcard.2003.08.072

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN： 0002-9149            Impact factor:   2.778


  16 in total

1.  Multi-parameter assessment of platelet inhibition and its stability during aspirin and clopidogrel therapy.

Authors:  A Anil Timur; Gurunathan Murugesan; Li Zhang; John Barnard; Deepak L Bhatt; Kandice Kottke-Marchant
Journal:  Thromb Res       Date:  2014-04-29       Impact factor: 3.944

Review 2.  Antiplatelet drug resistance and drug-drug interactions: Role of cytochrome P450 3A4.

Authors:  Wei C Lau; Paul A Gurbel
Journal:  Pharm Res       Date:  2006-10-24       Impact factor: 4.200

Review 3.  Antiplatelet resistance with aspirin and clopidogrel: is it real and does it matter?

Authors:  Wai-Hong Chen
Journal:  Curr Cardiol Rep       Date:  2006-07       Impact factor: 2.931

4.  Amyloid precursor protein 770 is specifically expressed and released from platelets.

Authors:  Saori Miura; Akiomi Yoshihisa; Tomofumi Misaka; Takayoshi Yamaki; Takao Kojima; Masahiro Toyokawa; Kazuei Ogawa; Hiroki Shimura; Naomasa Yamamoto; Kohji Kasahara; Yasuchika Takeishi; Shinobu Kitazume
Journal:  J Biol Chem       Date:  2020-07-23       Impact factor: 5.157

5.  Effects of persistent platelet reactivity despite aspirin therapy on cardiac troponin I and creatine kinase-MB levels after elective percutaneous coronary interventions.

Authors:  Oyku Gulmez; Aylin Yildirir; Gamze Kaynar; Didem Konas; Alp Aydinalp; Cagatay Ertan; Bulent Ozin; Haldun Muderrisoglu
Journal:  J Thromb Thrombolysis       Date:  2007-06-16       Impact factor: 2.300

6.  Sex differences in spontaneous reports on adverse bleeding events of antithrombotic treatment.

Authors:  Diana M Rydberg; Lennart Holm; Stefan Mejyr; Desirée Loikas; Karin Schenck-Gustafsson; Mia von Euler; Björn Wettermark; Rickard E Malmström
Journal:  Eur J Clin Pharmacol       Date:  2013-10-06       Impact factor: 2.953

7.  Prevalence and risk factors for aspirin and clopidogrel resistance in cerebrovascular stenting.

Authors:  S Prabhakaran; K R Wells; V H Lee; C A Flaherty; D K Lopes
Journal:  AJNR Am J Neuroradiol       Date:  2007-11-07       Impact factor: 3.825

Review 8.  Aspirin and clopidogrel hyporesponsiveness and nonresponsiveness in patients with coronary artery stenting.

Authors:  Rakesh K Sharma; Hanumanth K Reddy; Vibhuti N Singh; Rohit Sharma; Donald J Voelker; Girish Bhatt
Journal:  Vasc Health Risk Manag       Date:  2009-11-16

9.  Aspirin administered to women at 100 mg every other day produces less platelet inhibition than aspirin administered at 81 mg per day: implications for interpreting the women's health study.

Authors:  Lisa Swaim; Robert S Hillman
Journal:  J Thromb Thrombolysis       Date:  2008-08-07       Impact factor: 2.300

Review 10.  Aspirin resistance: an update.

Authors:  Gilead I Lancaster; Janardhan Srinivasan; Hitender Jain
Journal:  Curr Atheroscler Rep       Date:  2009-03       Impact factor: 5.113
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.